Leukemia is a cancer that develops in the bone marrow where blood cells are made.

Programs + Services | Doctors + Care Team | Research + Clinical Trials | News

Jason Law, MD

Accepting New Patients

Title(s): Chief, Pediatric Hematology Oncology; Site Principal Investigator, Children’s Oncology Group and Neuroblastoma Medulloblastoma Translational Research Consortium Trials; Director, Pediatric Bone Marrow Transplantation; Assistant Professor, Tufts University School of Medicine
Department(s): Pediatrics
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Pediatric hematology, oncology, bone marrow transplant

View Full Profile for Jason Law, MD

Cathy G. Rosenfield, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Co-Director, Tufts University School of Medicine Hematology Course; Associate Clinical Professor, Tufts University School of Medicine
Department(s): Pediatrics
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Hemophilia and other bleeding disorders, prothrombotic disorders, sickle cell and other hemoglobinopathies, general hematology

View Full Profile for Cathy G. Rosenfield, MD

Research + Clinical Trials

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.

This randomized phase III trial studies how well imatihib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
More information about research and clinical trials